NCT03929666 2025-09-12A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal CancerJazz PharmaceuticalsPhase 2 Completed74 enrolled
NCT02892123 2024-11-27Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing CancersJazz PharmaceuticalsPhase 1 Completed279 enrolled